The American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) both recognized the seminal contributions of the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/ EDIC) study, sponsored by the National Institute of Diabetes and Digestive and Kidney Diseases, by scheduling a dedicated DCCT/EDIC symposium in their respective programs "The DCCT/ EDIC study: 30 years of progress and contributions."
We are very grateful that both organizations provided the DCCT/EDIC Research Group this important opportunity to highlight our advances and contributions to improving the health and quality of life of people with type 1 diabetes (T1D). What follows in this issue are six articles summarizing the DCCT/EDIC, including 1) study background, goals, design, and general overview; 2) retinopathy outcomes; 3) neuropathy outcomes; 4) renal outcomes; 5) cardiovascular outcomes; and 6) collaborations and future directions. These articles represent a distillation of the presentations made at the ADA and EASD but because of space limitations are not a complete or comprehensive analysis of these DCCT/ EDIC topic areas. In addition, some of the major areas of DCCT/EDIC investigationdgenetic determinants of complications, epigenetic studies, evaluation of biomarkers, determinants of cardiovascular disease outcomes, etc.d have not been addressed in these articles.
The DCCT/EDIC is one of the most highly cited clinical research trials in diabetes. It has not only provided robust scientific answers with regards to T1D and its complications, but has provided the evidence necessary to establish new standards of care for T1D that are now universally accepted. The overarching lessons from the DCCT/EDIC can be summarized as follows. 
